Cite
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells
MLA
Antonio Bertolotto, et al. “Natalizumab Treatment Reduces L-Selectin (CD62L) in CD4+ T Cells.” Journal of Neuroinflammation, vol. 12, Feb. 2015. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c4141bd878bda00216fbab7aa83b20da&authtype=sso&custid=ns315887.
APA
Antonio Bertolotto, Michela Spadaro, Alessandra Lugaresi, Marzia Caldano, & Fabiana Marnetto. (2015). Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. Journal of Neuroinflammation, 12.
Chicago
Antonio Bertolotto, Michela Spadaro, Alessandra Lugaresi, Marzia Caldano, and Fabiana Marnetto. 2015. “Natalizumab Treatment Reduces L-Selectin (CD62L) in CD4+ T Cells.” Journal of Neuroinflammation 12 (February). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c4141bd878bda00216fbab7aa83b20da&authtype=sso&custid=ns315887.